GlassScriptPhysician profile
Paul Ziomek
NPI 1548357908
$3,515.23
in general payments reported to CMS, 2019-2025
18 companies · $70.65 in 2025
The $70.65 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,764 · 2020: $525 · 2021: $267 · 2022: $712 · 2023: $152 · 2024: $24.98 · 2025: $70.65.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $247.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $247.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $755.57 | 2022-2023 | Nuplazid |
| Novo Nordisk INC | $637.85 | 2019-2021 | |
| Amgen INC. | $593.90 | 2019-2022 | |
| Lilly USA, LLC | $391.46 | 2019-2025 | Trulicity, Baqsimi, Mounjaro |
| Janssen Pharmaceuticals, INC | $332.68 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $237.72 | 2019-2020 | |
| Gilead Sciences, INC. | $124.99 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $124.76 | 2019 | |
| Sanofi-Aventis U.S. LLC | $71.01 | 2020-2022 | |
| Boston Scientific Corporation | $68.78 | 2020-2022 | |
| Neurocrine Biosciences, INC. | $45.28 | 2024-2025 | Ingrezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.80 | 2020 | |
| Novartis Pharmaceuticals Corporation | $26.52 | 2019 | |
| Astellas Pharma US INC | $21.69 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.61 | 2025 | Caplyta |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $13.59 | 2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $13.44 | 2019 | |
| Glaxosmithkline, LLC. | $11.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Ziomek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.